Article Text
Statistics from Altmetric.com
METHOD
Design:
Prospective cohort study.
Setting:
European Schizophrenia Outpatient Health Outcomes study, Germany; recruitment January to December 2001.
Population:
2960 adult outpatients with DSM-IV schizophrenia either switching to or beginning a new antipsychotic (mean age 42 years; 49% male). Exclusions: IQ ⩽70, other DSM-IV schizophrenia spectrum disorders, bipolar I disorder, or psychotic disorder.
Prognostic factors:
Baseline predictors: age; gender; illness duration; symptoms (Clinical Global Impressions-Severity of Illness (CGI)-Schizophrenia scale overall severity score subscale scores). Functional predictors included occupational status, independent living and subjective wellbeing (Subjective Wellbeing Under Neuroleptic Treatment Scale (SWN-K)). Antipsychotic treatment factors included first antipsychotic, neurological side effects, and …
Footnotes
For correspondence: Martin Lambert, MD, Psychosis Early Detection and Intervention Centre, Centre for Psychosocial Medicine, Department of Psychiatry and Psychotherapy, University Medical Center Hamberg-Eppendorf, Martinistr 52, 20246 Hamburg, Germany; lambert{at}uke.uni-hamburg.de
Source of funding: Lilly Deutschland GmbH.
Footnotes
Competing interests: Dr McIntyre is a Consultant and Speaker for Astra-Zeneca, Eli Lilly, Janssen-Ortho, Organon, Wyeth, Lundbeck, GSK, Oryx, Biovail, Pfizer, Prestwick, BMS, and Shire; and has received research funding from Wyeth, GSK, Merck, Servier and Astra-Zeneca and Miss Soczynska received travel funds from Organon, Janssen Ortho.